

Supplementary Table 1. Univariate and multivariate analyses of the factors predictive of survival in treated patients

Variable	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Age	1.024	0.960-1.092	0.470			
Male gender	1.766	0.449-6.947	0.416			
Etiology						
Virus	1.332	0.332-5.355	0.686			
Alcohol	1.543	0.192-12.382	0.683			
Other	1.093	0.225-5.299	0.912			
Liver function						
Bilirubin	1.201	0.919-1.570	0.179			
INR	1.054	0.929-1.195	0.412			
Platelets	0.980	0.949-1.011	0.199			
Ascites	8.093	1.023-64.003	0.047	6.289	0.757-52.247	0.079
Varices	1.114	0.138-8.973	0.920			
EBL prior to PVT	0.929	0.238-3.618	0.915			
EBL prior to anticoagulant therapy	0.650	0.187-2.258	0.498			
Variceal bleeding 6 months prior to PVT	1.030	0.128-8.270	0.978			
Bleeding at PVT diagnosis	1.444	0.400-5.214	0.575			
Tumor						
HCC at PVT diagnosis	1.345	0.510-3.549	0.549			
HCC prior to PVT	1.669	0.208-13.410	0.630			
Treatment HCC	0.038	0.000-58.644	0.382			
Infection at PVT diagnosis	1.233	0.152-9.994	0.845			
Portal vein trunk (N;%)	33.371	0.085-13081	0.250			
Partial	Reference					
Complete	2.901	0.980-8.583	0.054	1.973	0.668-5.829	0.997
Intrahepatic branches	3.226	0.681-15.285	0.140			
Partial	Reference					
Complete	1.865	0.731-4.761	0.192			
Splenic vein	1.172	0.146-9.411	0.881			
Partial	Reference					
Complete	1.172	0.146-9.411	0.881			
Superior mesenteric vein	1.536	0.395-5.968	0.536			
Partial	Reference					
Complete	1.464	0.395-5.424	0.568			
Cavernoma (N;%)	1.267	0.158-10.147	0.824			
Splenomegaly (N;%)	21.124	0.000-1.030	0.736			
Interval to the beginning of therapy						
≤ 6 months	Reference					
> 6 months	1.877	0.235-14.961	0.552			
Type of treatment						
LMWH	0.894	0.223-3.590	0.875			
VKA	0.401	0.082-1.952	0.258			
Fondaparinux	0.482	0.060-3.867	0.492			
Dose						
Half dose (once daily)	Reference					
Full dose (twice daily)	0.776	0.163-3.686	0.750			
Therapy duration	0.969	0.921-1.081	0.213			
Recanalization after therapy	0.570	0.159-2.048	0.389			
Time between start of therapy and recanalization	0.854	0.631-1.155	0.305			
Progression of PVT during therapy	2.142	0.252-18.165	0.485			
Beta-blockers during therapy	0.524	0.147-1.869	0.319			

Abbreviations: HR: hazard rate; CI: confidence interval; INR: International Normalized Ratio; EBL: endoscopic band ligation; HCC: hepatocellular carcinoma; LMWH low molecular weight heparin; VKA: vitamin K antagonist

For Peer Review

Supplementary Table 2. Univariate and multivariate analyses of the factors predictive of survival in treated patients who showed PVT relapse or progression at the end of therapy

Variable	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Age	1.075	0.961-1.307	0.202			
Male gender	1.546	0.309-7.726	0.596			
Etiology						
Virus	1.182	0.235-5.944	0.839			
Alcohol	1.551	0.181-13.292	0.689			
Other	1.777	0.316-9.974	0.514			
Liver function						
Bilirubin	1.157	0.863-1.552	0.331			
INR	1.131	0.943-1.356	0.185			
Platelets	0.972	0.925-1.022	0.274			
Ascites	48.026	0.057-40256.226	0.260			
Varices	1.246	0.145-10.737	0.841			
EBL prior to therapy	1.033	0.120-8.911	0.977			
Variceal bleeding 6 months prior to PVT	0.350	0.064-1.914	0.226			
Bleeding at PVT diagnosis	21.705	0.000-1.210E	0.765			
	2.026	0.405-10.152	0.390			
Tumor						
HCC at PVT diagnosis	5.458	0.974-30.580	0.054	5.708	0.926-35.178	0.237
HCC prior to PVT	1.112	0.128-9.686	0.923			
Treatment HCC	0.043	0.000-12883	0.624			
Infection at PVT diagnosis	1.065	0.123-9.248	1.065			
Portal vein trunk						
Partial	31.779	0.009-116465.0	0.409			
Complete	Reference					
	3.834	0.941-15.618	0.061	4.469	0.930-21.473	0.189
Intrahepatic branches						
Partial	2.868	0.523-15.722	0.225			
Complete	Reference					
	1.768	0.633-4.940	0.277			
Splenic vein						
Partial	26.223	0.002-369048.4	0.503			
Complete	Reference					
	26.223	0.002-369048.4	0.503			
Superior mesenteric vein						
Partial	1.822	0.213-15.611	0.584			
Complete	Reference					
	1.822	0.213-15.611	0.584			
Cavernoma						
	4.448	0.493-40.106	0.183			
Interval to the start of therapy						
≤ 6 months	Reference					
> 6 months	1.079	0.117-9.919	0.946			
Type of treatment						
LMWH	0.450	0.090-2.244	0.875			
VKA	0.245	0.044-1.348	0.106			
Fondaparinux	0.791	0.092-6.815	0.831			
Dose						
Daily	Reference					
Twice daily	0.459	0.053-3.953	0.478			
Therapy duration (months)						
Recanalization after therapy	0.947	0.861-1.041	0.261			
Time between start therapy and recanalization	0.745	0.148-3.749	0.721			
Progression PVT during therapy	0.878	0.650-1.186	0.396			
Beta-blockers during therapy	1.777	0.345-9.166	0.492			
	0.303	0.061-1.502	0.144			

Abbreviations: HR: hazard rate; CI: confidence level; INR: International Normalized Ratio; EBL: endoscopic band ligation; PVT: portal vein thrombosis; HCC: hepatocellular carcinoma; LMWH low molecular weight heparin; VKA: vitamin K antagonists

Supplementary Table 3. Subgroup analysis of the treatment outcomes according to the CTP class.

	<u>CPT-A treated (n=43)</u>	<u>CPT-B treated (n=33)</u>	<u>CPT-C treated (n=5)</u>	<u>P value</u>
<u>Recanalization rate</u>	<u>27 (62.8)</u>	<u>19 (57.6)</u>	<u>0</u>	<u>0.027</u>
<u>Recurrence of PVT after stopping treatment</u>	<u>13 (30.2)</u>	<u>4 (12.1)</u>	<u>0</u>	<u>0.716</u>
<u>PVT progression</u>	<u>8 (18.6)</u>	<u>8 (24.2)</u>	<u>1 (20.0)</u>	<u>0.692</u>
<u>Bleeding rate*</u>	<u>6 (14.0)</u>	<u>8 (24.2)</u>	<u>2 (40.0)</u>	<u>0.269</u>
<u>Survival (months)**</u>	<u>72.7 (72.1-73.2)</u>	<u>62.0 (48.0-75.9)</u>	<u>34.6 (16.3-52.9)</u>	<u>0.003</u>

Abbreviations: CTP: Child-Turcotte-Pugh; PVT: portal vein thrombosis

Categorical variables are expressed as number and percentage; survival is expressed in months (mean and 95% CI).

*Bleeding rates in untreated patients were 16.2% in CPT-A, 28.9% in CPT-B and 15.8% in CPT-C.

** Survival in untreated patients was 73.9 months in CPT-A, 56.1 months in CPT-B and 18.2 months in CPT-C.